Q&A: New approaches are needed to find better cancer drug targets
Bill Sellers, head of Broad’s Cancer Program, talks about how to discover new classes of genetic dependencies that could move therapies closer to curing cancer patients.
Bill Sellers is the head of Broad's Cancer Program.